Officials with Janssen Therapeutics announced the submission of a supplemental new drug application to the Food and Drug Administration to update the label for once-daily, all-oral simeprevir (Olysio) in combination with sofosbuvir for adults with genotype 1 chronic hepatitis C (CHC) infection with or without cirrhosis.
The application is based on results from two phase-3 trials. OPTIMIST-1 is a randomized, open-label trial to investigate the efficacy and safety of the all-oral regimen of simeprevir and sofosbuvir (SMV/SOF) among treatment-naive and treatment-experienced genotype 1 CHC patients without cirrhosis.
The primary study endpoint is sustained virologic response (SVR) at 12 weeks after treatment (SVR12) with 12 and eight weeks of treatment with SMV/SOF versus a historical control.
About 97% of patients treated with SMV/SOF for 12 weeks (n=150/155) achieved SVR12, which was superior to the SVR12 rate of 87% among the historical control.
OPTIMIST-2 is an open-label, single-arm trial to investigate the efficacy and safety of SMV/SOF in treatment-naive and treatment-experienced genotype 1 CHC patients with cirrhosis. The primary endpoint is SVR12 with SMV/SOF versus a historical control.
weeks of treatment with SMV/SOF resulted in SVR12 rates of 84% (n=86/103), which was superior to the SVR12 rate of 70% in the historical control.
Simeprevir (Olysio) is an NS3/4A protease inhibitor. Sofosbuvir (Gilead) is a nucleotide analog NS5B polymerase inhibitor.
This article originally appeared on MPR